Startup · $15m raised
Melbourne, VIC
Every investor coverage indicates participated in a round Cartherics raised.
Companies Cartherics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Bob Moses | Chairman | Forbes Australia |
| Dr Ian Nisbet | CEO | Wholesale Investor |
| Professor Alan Trounson | CEO · Founder | Forbes Australia |
Stories naming Cartherics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Melbourne biotech Cartherics, which is extending its off-the-shelf cell therapy platform from ovarian cancer to endometriosis; its CEO outlines a capital raise in progress and 2026 clinical trial plans.
A Melbourne biotechnology firm developing a CAR-NK cell therapy for ovarian cancer has completed a fifteen-million-dollar raise to fund its first trial in humans and work toward other cancers.